Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.
Hussein AlnajarHiranmayi RavichandranAndré Figueiredo RendeiroKentaro OharaWael Al ZoughbiJyothi ManoharNoah GrecoMichael SigourosJesse FoxEmily MuthSamuel AngiuoliBishoy FaltasMichael ShustermanCora N SternbergOlivier ElementoJuan Miguel MosqueraPublished in: Cold Spring Harbor molecular case studies (2022)
Sarcomatoid urothelial carcinoma (SUC) is a rare subtype of urothelial carcinoma (UC) that typically presents at an advanced stage compared to more common variants of UC. Locally advanced and metastatic UC have a poor long-term survival following progression on first-line platinum-based chemotherapy. Antibodies directed against the programmed cell death 1 protein (PD-1) or its ligand (PD-L1) are now approved to be used in these scenarios. The need for reliable biomarkers for treatment stratification is still under research. Here, we present a novel case report of the first Imaging Mass Cytometry (IMC) analysis done in SUC to investigate the immune cell repertoire and PD-L1 expression in a patient who presented with metastatic SUC and experienced a prolonged response to the anti-PD1 immune checkpoint inhibitor pembrolizumab after progression on first-line chemotherapy. This case report provides an important platform for translating these findings to a larger cohort of UC and UC variants.
Keyphrases
- case report
- locally advanced
- squamous cell carcinoma
- small cell lung cancer
- high resolution
- rectal cancer
- neoadjuvant chemotherapy
- copy number
- single cell
- advanced non small cell lung cancer
- stem cells
- radiation therapy
- phase ii study
- climate change
- high throughput
- mass spectrometry
- gene expression
- epidermal growth factor receptor
- study protocol
- open label
- high throughput sequencing